Multiple sclerosis patients urge FDA to approve drug
In November, the Food and Drug Administration rejected a drug for multiple sclerosis that its sister agencies in Europe, Canada, Mexico and Australia had approved. Doctors and patients who want access to the drug Lemtrada have launched a lobbying campaign to get the regulatory agency to change its mind. "Lemtrada appears to be among our most effective, if not the most effective agent in reducing relapses," said Aaron Miller, MD, Professor of Neurology at the Icahn School of Medicine at Mount Sinai, and Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai Health System.
-Dr. Aaron Miller, Professor, Neurology, Icahn School of Medicine at Mount Sinai, Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Health System
New Study Details The Various Ways Patients with Multiple Sclerosis Develop Impairment
Feb 22, 2022 View All Press Releases
Two Mount Sinai Experts Receive Honors From the National Multiple Sclerosis Society
Sep 16, 2021 View All Press Releases